Increase in miR-221 expression and repression of its target genes (such as proapoptotic BMF and cyclin-dependent kinase inhibitor p27/57) have been revealed in the liver of a miR-221 transgenic mouse model, and in vivo delivery of anti-miR-221 oligonucleotides can lead to significant reduction of the number and size of tumor nodules (23). Here, CDKN1B is linked to neoplasm.